Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes

Drug Name (Brand / Generic)

Lipaglyn / saroglitazar

Developed By

Zydus Cadila

Therapy Class

Dual PPAR agonist

Current Indication

Diabetic dyslipidemia or hypertriglyceridemia in type II diabetes

Market Sector

Diabetes

Development Status

Approved in India
Expand

Go Top